MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Genetic and Clinical Analysis of Cerebral Calcifications

V. Chelban, R. Kaiyrzhanov, H. Houlden (London, United Kingdom)

Meeting: 2017 International Congress

Abstract Number: 435

Keywords: Calcium, Familial neurodegenerative diseases, Parkinsonism

Session Information

Date: Tuesday, June 6, 2017

Session Title: Genetics (Non-PD)

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: Genetic and clinical analysis in primary cerebral calcification.

Background: Cerebral calcification is associated with a variety of disorders of different aetiologies. To date, the primary form of cerebral calcification is thought to be a genetically and clinically heterogeneous disease with variable penetrance within and between families. There are currently four known genes responsible for primary familial brain calcification, SLC20A2 being the most prevalent one. However, almost half the patients with primary familial brain calcification remain without a genetic diagnosis. 

Methods: In-depth, phenotype-genotype and radiological analysis of patients with cerebral calcifications. Genetic testing was performed using Whole Exome Sequencing. Visual calcification rating of total calcification scores(TCC) was performed by two separate investigators.

Results: We analysed 58 cases of brain calcifications suggestive of Fahr’s syndrome of which 72% presented with primary brain calcification and 28% had secondary forms. Whole exome sequencing was performed in 32 patients and identified a causal mutation in 17.4% of cases. The most frequent gene in this cohort was SLC20A2.  In the familial form, movement disorders (65%), psychiatric (60%) and cognitive symptoms (56%) were most common clinical presentation with high familial and interfamilial variability. In the secondary forms, 12.5% of cases had a mitochondrial disorder presenting with cerebral calcification and 15.5% were due to other pathology. One case presented with isolated, heavy pontine calcification.  TCC scores were highly variable even within family members and there was no correlation with age or progression .

Conclusions: The largest UK series of genetic and clinical analysis of cerebral calcification shows high phenotype variability and calcification patterns, absence of calcification score correlations and contributes with novel mutations. Less than one third of the patients with primary familial brain calcification were found to have a genetic cause suggesting further thorough genetic studies are necessary with potential for the discovery of new causal genes.

To cite this abstract in AMA style:

V. Chelban, R. Kaiyrzhanov, H. Houlden. Genetic and Clinical Analysis of Cerebral Calcifications [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/genetic-and-clinical-analysis-of-cerebral-calcifications/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/genetic-and-clinical-analysis-of-cerebral-calcifications/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley